Alvotech
| NASDAQ: ALVO | Healthcare / Drug Manufacturers / Luxembourg |
| 9.11 | -0.0500 | -0.55% | Vol 2.86K | 1Y Perf 32.37% |
| Oct 4th, 2023 15:35 DELAYED |
| BID | 9.10 | ASK | 9.31 | ||
| Open | 9.10 | Previous Close | 9.16 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 13.20 | Analyst Rating | Hold 3.00 | |
| Potential % | 44.90 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 39.54 | Earnings Rating | — | |
| Market Cap | 2.40B | Earnings Date | 30th Aug 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.22 | |
| Beta | -0.47 |
Today's Price Range 9.109.30 | 52W Range 5.5214.60 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.46% | ||
| 1 Month | -7.85% | ||
| 3 Months | 8.66% | ||
| 6 Months | -30.61% | ||
| 1 Year | 32.37% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -21.89 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | 8.88 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 1.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 258.60 | ||||
| - | ||||
| - | ||||
| - | ||||
| -9.30 | ||||
| -1.28 | ||||
| -8.58 | ||||
| - | ||||
| - | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 0.80 | ||||
| - | ||||
| - | ||||
| 2.90 | ||||
| Leverage Ratio | -2.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 62.40 | ||||
| 75.60 | ||||
| 96.50 | ||||
| - | ||||
| 22.84 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.14 | -0.43 | -207.14 |
| Q01 2023 | - | -1.24 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.14 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 2.86K |
| Shares Outstanding | 263.51K |
| Shares Float | 63.24M |
| Trades Count | 41 |
| Dollar Volume | 26.41K |
| Avg. Volume | 53.87K |
| Avg. Weekly Volume | 36.64K |
| Avg. Monthly Volume | 29.92K |
| Avg. Quarterly Volume | 95.05K |
Alvotech (NASDAQ: ALVO) stock closed at 9.16 per share at the end of the most recent trading day (a 1.55% change compared to the prior day closing price) with a volume of 26.58K shares and market capitalization of 2.40B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 0 people. Alvotech CEO is .
The one-year performance of Alvotech stock is 32.37%, while year-to-date (YTD) performance is -8.4%. ALVO stock has a five-year performance of %. Its 52-week range is between 5.52 and 14.6, which gives ALVO stock a 52-week price range ratio of 39.54%
Alvotech currently has a PE ratio of 258.60, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 8.88%, a ROC of -% and a ROE of -21.89%. The company’s profit margin is 22.84%, its EBITDA margin is 96.50%, and its revenue ttm is $0.00 , which makes it $- revenue per share.
Of the last four earnings reports from Alvotech, there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Alvotech’s next earnings report date is -.
The consensus rating of Wall Street analysts for Alvotech is Hold (3), with a target price of $13.2, which is +44.90% compared to the current price. The earnings rating for Alvotech stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alvotech has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alvotech has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.92, ATR14 : 0.36, CCI20 : 10.51, Chaikin Money Flow : -0.24, MACD : -0.09, Money Flow Index : 55.65, ROC : 0.22, RSI : 49.72, STOCH (14,3) : 73.11, STOCH RSI : 1.00, UO : 32.32, Williams %R : -26.89), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alvotech in the last 12-months were:
Alvotech
Alvotech is a integrated biopharmaceutical company committed to developing and manufacturing high quality biosimilar medicines for patients globally. The company's purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
CEO:
Telephone: +352 4224500
Address: 9, rue de Bitbourg, Luxembourg L-1273, , LU
Number of employees: 0
